Bevacizumab is a humanised monoclonal antibody that binds to all isoforms of VEGF.9 By binding to VEGF and preventing it from interacting with its receptors, bevacizumab inhibits angiogenesis and leads to the regression of newly formed microvessels and the ‘normalisation' of abnormal tumour vascularisation.15,16 Inhibition of VEGF is also directly related to the development of hypertension, a recognised class effect of anti-angiogenic therapies, including bevacizumab. Here, VEGFA is linked to neoplasm.